Tenapanor (Ibsrela)

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Irritable Bowel Syndrome with Constipation

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (1)
CA
  • IBSRELA (tenapanor) for irritable bowel syndrome with constipation in adults (Knight release dated 2020-04-17)
Product first approved 2020knighttx.com

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (7)
Irritable Bowel Syndrome with Constipation
NCT05905926 · Ardelyx
2023-02-17 – 2031-10 · Irritable Bowel Syndrome With Constipation (IBS-C)
What this study did
NCT05643534 · Ardelyx
2022-11-15 – 2026-08-20 · Irritable Bowel Syndrome With Constipation (IBS-C)
What this study did
NCT02727751 · Ardelyx
2016-03 – 2017-10 · Constipation Predominant Irritable Bowel Syndrome
What this study did
Other / comorbidity
NCT06810167 · Massachusetts General Hospital
2025-06-01 – 2027-06-30 · Cystic Fibrosis, Constipation
What this study did
NCT07382167 · Ardelyx
2026-01-13 – 2027-06-04 · Chronic Idiopathic Constipation (CIC)
What this study did
Phase 2/3 (1)
Irritable Bowel Syndrome with Constipation
NCT01923428 · Ardelyx
2013-08 – 2014-10 · Constipation Predominant Irritable Bowel Syndrome
What this study did
Phase 2 (3)
Irritable Bowel Syndrome with Constipation
NCT06553547 · Ardelyx
2024-07-24 – 2026-07-07 · Irritable Bowel Syndrome With Constipation (IBS-C)
What this study did
NCT01340053 · Ardelyx
2011-05 – 2012-02 · Constipation Predominant Irritable Bowel Syndrome
What this study did
Other / comorbidity
NCT06460038 · Cedar Valley Digestive Health Center
2025-01-01 – 2027-03 · Synucleinopathy, Parkinson's Disease
What this study did
Phase 1 (10)
Other / comorbidity
NCT06203444 · Ardelyx
2023-11-27 – 2024-05-30 · Lactation
What this study did
NCT02140281 · Ardelyx
2014-05 – 2014-08 · Healthy Volunteers
What this study did
NCT02140268 · Ardelyx
2014-05 – 2014-08 · Healthy Volunteers
What this study did
NCT02063386 · Ardelyx
2014-04 – 2014-05 · Healthy Volunteers
What this study did
NCT02176252 · Ardelyx
2013-07 – 2013-12 · Healthy Volunteer
What this study did
NCT02226783 · Ardelyx
2013-03 – 2013-10 · Healthy Volunteers Food Interaction Study
What this study did
NCT02346890 · Ardelyx
2013-04 – 2013-04 · Healthy
What this study did
NCT02249936 · Ardelyx
2013-02 – 2013-02 · Healthy
What this study did
NCT02796131 · Ardelyx
2011-07 – 2012-04 · Healthy
What this study did
NCT02819687 · Ardelyx
2010-11 – 2011-08 · Healthy
What this study did
Phase 4 (2)
Irritable Bowel Syndrome with Constipation
NCT05995899 · Kyle Staller, MD, MPH
2024-02-06 – 2025-12-17 · IBS, IBS - Irritable Bowel Syndrome
What this study did
Other / comorbidity
NCT06481150 · University of Texas Southwestern Medical Center
2024-07-01 – 2025-09-14 · Hyperoxaluria
What this study did

Competitive landscape

Other NHE3 (sodium/hydrogen exchanger isoform 3) drugs

Tenapanor (Xphozah). Compare all 2 NHE3 (sodium/hydrogen exchanger isoform 3) drugs

1 other tracked programme targets this mechanism, none of them ahead of this one.

This drug's own stage for Irritable Bowel Syndrome with Constipation: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Tenapanor (Ibsrela): this drugApprovedSmall moleculeNHE3 (sodium/hydrogen exchanger isoform 3)Reliable signalNo reviewed efficacy summary in this indication
Linaclotide (Linzess)ApprovedPeptideGuanylate cyclase-C (GC-C)Weak signal
NCT03573908: Overall Change From Baseline in Abdominal Score (Abdominal Bloating, Abdominal Discomfort, and Abdominal Pain) Throughout the Treatment Period (Baseline (14 days before randomization up to the time of randomization), Treatment Period (Weeks 1-12)): Placebo -1.182 score on a scale (Standard Error 0.109) | Linaclotide 290 µg -1.898 score on a scale (Standard Error 0.111)
Tenapanor (Xphozah)
Approved(overall)
Small moleculeNHE3 (sodium/hydrogen exchanger isoform 3)
Reliable signal(overall)
No reviewed efficacy summary in this indication
Brenipatide
Phase 3(overall)
PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Tenapanor (Ibsrela) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 2Synucleinopathy, Parkinson's DiseaseRecruiting
Est. primary completion 2026-12 · NCT06460038 · CT.gov ↗
What to watch
2027 (1)
February 2027 (1)
Phase 3Chronic Idiopathic Constipation (CIC)Recruiting
Est. primary completion 2027-02-26 · NCT07382167 · CT.gov ↗
What to watch
2031 (1)
July 2031 (1)
Phase 3Irritable Bowel Syndrome with ConstipationEnrolling by invitation
Est. primary completion 2031-07 · NCT05905926 · CT.gov ↗
What to watch

See the full readout calendar ↗